TrialSignal
Clinical trial intelligence report
A Randomized Controlled, Open-lable, Phase III, Multicenter Clinical Study of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT04951648
Status
UNKNOWN
Phase
PHASE3
Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Executive brief
Investment-Ready Snapshot
To assess the efficacy and safety of Almonertinib versus platinum-based chemotherapy as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutation.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04951648
Indication
Non-small Cell Lung Cancer
Modality
small molecule
Target
Almonertinib, chemotherapy
Intervention
Almonertinib, chemotherapy
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.